Core Viewpoint - SINOVAC Biotech Ltd. has appointed UHY LLP as its independent auditor, marking a significant step towards improving transparency and resuming trading on NASDAQ [1][3]. Company Overview - SINOVAC is a leading biopharmaceutical company in China, focusing on the research, development, manufacturing, and commercialization of vaccines for infectious diseases [3][4]. - The company's product portfolio includes vaccines for COVID-19, hepatitis A, and other infectious diseases [4][5]. Auditor Engagement - UHY will audit SINOVAC's financial statements for the years ending December 31 from 2021 to 2025, including internal control audits for 2024 and 2025 [2]. - The company plans to file Form 20Fs and Form 6-Ks to comply with SEC and NASDAQ requirements [2]. Commitment to Transparency - The appointment of UHY is seen as a commitment to robust financial oversight and transparency, facilitating the goal of resuming trading on NASDAQ [3]. Future Plans - SINOVAC is dedicated to ongoing vaccine research and development, with plans to explore global market opportunities and enhance trade and cooperation with other countries [7].